acarbose 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
39 56180-94-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • acarbose
  • ascarbose
  • glucobay
  • prandase
  • precose
An inhibitor of ALPHA-GLUCOSIDASES that retards the digestion and absorption of DIETARY CARBOHYDRATES in the SMALL INTESTINE.
  • Molecular weight: 645.61
  • Formula: C25H43NO18
  • CLOGP: -6.66
  • LIPINSKI: 3
  • HAC: 19
  • HDO: 14
  • TPSA: 321.17
  • ALOGS: -0.64
  • ROTB: 9
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.64 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 2 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.32 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.20 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.70 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 129 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK1,NTRK2,PDK2,PDK4,PIK3CD,PRKDC,SIK2,STK33,TEK 26
kinase-selectivity-class ACVRL1,CHUK,MAP2K6,PDK1,ZAP70 5
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Sept. 6, 1995 FDA BAYER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 737.49 22.31 260 7306 69588 90551293
Hypoglycaemic coma 512.24 22.31 102 7464 2888 90617993
Diabetes mellitus inadequate control 157.12 22.31 59 7507 18625 90602256
Lactic acidosis 125.62 22.31 68 7498 50395 90570486
Abdominal distension 124.21 22.31 96 7470 130505 90490376
Neuroglycopenia 82.17 22.31 19 7547 1096 90619785
Unresponsive to stimuli 80.17 22.31 46 7520 38075 90582806
Respiratory rate increased 77.46 22.31 34 7532 15967 90604914
Hyperkalaemia 75.69 22.31 54 7512 64910 90555971
Diabetic ketoacidosis 75.30 22.31 38 7528 24369 90596512
Peripheral circulatory failure 75.30 22.31 19 7547 1585 90619296
Blood cholesterol decreased 62.37 22.31 17 7549 1914 90618967
Melaena 60.13 22.31 37 7529 34760 90586121
Stupor 56.03 22.31 20 7546 5462 90615419
Gastric polyps 55.25 22.31 19 7547 4653 90616228
Drug interaction 54.49 22.31 89 7477 276364 90344517
Blood glucose decreased 53.92 22.31 30 7536 23399 90597482
Hyperhidrosis 52.97 22.31 61 7505 136244 90484637
Blood urea increased 51.68 22.31 32 7534 30381 90590500
Atrioventricular block first degree 50.85 22.31 21 7545 8490 90612391
Blood potassium increased 48.93 22.31 27 7539 20722 90600159
Pneumatosis intestinalis 48.64 22.31 16 7550 3421 90617460
Bradykinesia 48.33 22.31 19 7547 6769 90614112
Ketoacidosis 48.22 22.31 18 7548 5577 90615304
Dizziness 45.96 22.31 130 7436 589154 90031727
Altered state of consciousness 43.26 22.31 29 7537 31503 90589378
Hyperglycaemia 43.07 22.31 35 7531 50935 90569946
Initial insomnia 42.53 22.31 19 7547 9291 90611590
Blood glucose abnormal 42.18 22.31 19 7547 9473 90611408
Acute kidney injury 41.42 22.31 86 7480 320301 90300580
Hepatic function abnormal 39.56 22.31 32 7534 46256 90574625
Hypotonia 38.82 22.31 19 7547 11407 90609474
Peripheral artery haematoma 38.26 22.31 6 7560 39 90620842
Cold sweat 37.88 22.31 20 7546 14061 90606820
Muscle rigidity 37.58 22.31 20 7546 14289 90606592
Multiple drug therapy 37.54 22.31 16 7550 6993 90613888
Asthenia 36.09 22.31 112 7454 533639 90087242
Dysuria 35.29 22.31 28 7538 39373 90581508
Intestinal transit time abnormal 35.12 22.31 6 7560 70 90620811
Urinary incontinence 34.30 22.31 27 7539 37539 90583342
Flatulence 34.09 22.31 28 7538 41339 90579542
Glycosylated haemoglobin increased 33.29 22.31 19 7547 15543 90605338
Parkinsonism 32.33 22.31 18 7548 14047 90606834
Urine calcium/creatinine ratio increased 32.24 22.31 6 7560 117 90620764
Syncope 32.10 22.31 47 7519 132616 90488265
Mucosal erosion 31.89 22.31 10 7556 1835 90619046
Blood lactic acid increased 31.03 22.31 15 7551 8763 90612118
Peptic ulcer 30.99 22.31 13 7553 5462 90615419
Insulin-like growth factor decreased 30.25 22.31 7 7559 405 90620476
Motor dysfunction 29.58 22.31 19 7547 19211 90601670
Bite 28.57 22.31 7 7559 517 90620364
Pain 28.35 22.31 25 7541 996316 89624565
Protein urine present 27.95 22.31 13 7553 6971 90613910
Urethral caruncle 27.46 22.31 5 7561 86 90620795
Micturition disorder 27.06 22.31 10 7556 3010 90617871
Mucosal dryness 26.60 22.31 10 7556 3157 90617724
Drug ineffective 26.60 22.31 47 7519 1384251 89236630
Blood sodium increased 26.55 22.31 10 7556 3172 90617709
Blood pressure decreased 26.54 22.31 32 7534 74863 90546018
Haematemesis 26.07 22.31 22 7544 33704 90587177
Blood creatine increased 24.91 22.31 12 7554 6955 90613926
Hiatus hernia 24.83 22.31 19 7547 25342 90595539
Loss of consciousness 24.71 22.31 43 7523 140195 90480686
Swelling 24.68 22.31 3 7563 419055 90201826
Glucose urine present 24.64 22.31 7 7559 917 90619964
Blood creatinine increased 24.63 22.31 36 7530 101350 90519531
Drug dependence 24.48 22.31 20 7546 29307 90591574
Dementia 23.63 22.31 18 7548 23843 90597038
Atrial fibrillation 23.59 22.31 41 7525 133570 90487311
Cell death 23.33 22.31 9 7557 3046 90617835
Nausea 23.19 22.31 165 7401 1110151 89510730
Pancreatitis acute 22.89 22.31 20 7546 32095 90588786
Lacunar infarction 22.46 22.31 9 7557 3368 90617513
Blood pressure systolic increased 22.45 22.31 26 7540 58319 90562562

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemic coma 318.37 20.48 74 5716 2670 42612875
Hypoglycaemia 311.91 20.48 155 5635 59699 42555846
Abdominal distension 92.30 20.48 77 5713 71658 42543887
Lactic acidosis 85.38 20.48 61 5729 45200 42570345
Diabetes mellitus inadequate control 77.33 20.48 39 5751 15351 42600194
Cerebral infarction 61.04 20.48 43 5747 31126 42584419
Flatulence 49.94 20.48 35 5755 25117 42590428
Hyperoxaluria 44.72 20.48 9 5781 161 42615384
Ketosis 38.57 20.48 11 5779 894 42614651
Albumin urine present 36.96 20.48 9 5781 395 42615150
Hepatic function abnormal 36.79 20.48 40 5750 51527 42564018
Unresponsive to stimuli 34.81 20.48 31 5759 31372 42584173
Palpitations 33.81 20.48 38 5752 50759 42564786
Respiratory rate increased 33.30 20.48 20 5770 11042 42604503
Diabetic metabolic decompensation 33.16 20.48 12 5778 2090 42613455
Diabetic ketosis 29.88 20.48 7 5783 260 42615285
Liver injury 29.77 20.48 23 5767 19125 42596420
Speech disorder 28.86 20.48 27 5763 29094 42586451
Drug interaction 27.40 20.48 89 5701 266910 42348635
Pneumatosis intestinalis 26.69 20.48 13 5777 4739 42610806
Mast cell degranulation present 26.13 20.48 5 5785 68 42615477
Mouth swelling 25.21 20.48 10 5780 2236 42613309
Quadriparesis 24.77 20.48 10 5780 2340 42613205
Drug-induced liver injury 22.72 20.48 27 5763 38246 42577299
Death 22.11 20.48 19 5771 471166 42144379
Hyperhidrosis 21.97 20.48 42 5748 90470 42525075
Blood glucose decreased 21.92 20.48 17 5773 14202 42601343
Blood glucose fluctuation 21.21 20.48 11 5779 4576 42610969

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 969.87 18.83 400 12624 115704 110460571
Hypoglycaemic coma 816.84 18.83 177 12847 5356 110570919
Diabetes mellitus inadequate control 212.39 18.83 92 12932 29683 110546592
Abdominal distension 210.09 18.83 170 12854 174933 110401342
Lactic acidosis 195.94 18.83 127 12897 92684 110483591
Unresponsive to stimuli 109.90 18.83 77 12947 63713 110512562
Respiratory rate increased 105.97 18.83 54 12970 25029 110551246
Diabetic ketoacidosis 87.31 18.83 57 12967 42001 110534274
Flatulence 83.01 18.83 60 12964 52089 110524186
Hyperkalaemia 79.97 18.83 89 12935 135707 110440568
Hyperhidrosis 76.50 18.83 102 12922 187196 110389079
Neuroglycopenia 75.48 18.83 19 13005 1107 110575168
Hepatic function abnormal 75.25 18.83 71 12953 89224 110487051
Drug interaction 73.88 18.83 174 12850 500009 110076266
Blood glucose decreased 73.82 18.83 45 12979 29443 110546832
Peripheral circulatory failure 66.45 18.83 19 13005 1800 110574475
Pneumatosis intestinalis 66.21 18.83 28 12996 8501 110567774
Ketoacidosis 61.70 18.83 28 12996 10059 110566216
Cerebral infarction 59.23 18.83 49 12975 51789 110524486
Dizziness 58.75 18.83 198 12826 697995 109878280
Melaena 58.55 18.83 55 12969 68702 110507573
Blood glucose abnormal 55.11 18.83 28 12996 12888 110563387
Gastric polyps 52.63 18.83 21 13003 5502 110570773
Blood cholesterol decreased 50.87 18.83 17 13007 2699 110573576
Palpitations 49.24 18.83 76 12948 159136 110417139
Glycosylated haemoglobin increased 48.98 18.83 32 12992 23587 110552688
Acute kidney injury 47.18 18.83 173 12851 635257 109941018
Altered state of consciousness 46.97 18.83 45 12979 57581 110518694
Ketosis 45.24 18.83 14 13010 1740 110574535
Diabetic ketosis 44.40 18.83 12 13012 924 110575351
Hyperoxaluria 44.33 18.83 10 13014 363 110575912
Cold sweat 43.62 18.83 29 12995 22002 110554273
Stupor 41.44 18.83 20 13004 8245 110568030
Speech disorder 40.84 18.83 43 12981 61526 110514749
Atrioventricular block first degree 38.94 18.83 23 13001 14202 110562073
Albumin urine present 37.35 18.83 10 13014 743 110575532
Initial insomnia 37.12 18.83 20 13004 10369 110565906
Drug ineffective 36.65 18.83 78 12946 1520462 109055813
Hyperglycaemia 35.71 18.83 47 12977 85043 110491232
Glucose urine present 33.83 18.83 12 13012 2277 110573998
Bradykinesia 33.68 18.83 19 13005 10769 110565506
Asthenia 33.52 18.83 165 12859 688834 109887441
Nausea 33.46 18.83 254 12770 1235436 109340839
Chronic gastritis 33.03 18.83 15 13009 5396 110570879
Blood potassium increased 33.01 18.83 29 12995 33220 110543055
Drug-induced liver injury 32.56 18.83 54 12970 120013 110456262
Parkinsonism 31.85 18.83 24 13000 22163 110554112
Intestinal transit time abnormal 30.90 18.83 6 13018 103 110576172
Blood glucose fluctuation 30.85 18.83 16 13008 7682 110568593
Blood urea increased 30.58 18.83 35 12989 54922 110521353
Fatigue 30.41 18.83 61 12963 1215897 109360378
Multiple drug therapy 30.24 18.83 16 13008 7998 110568277
Peripheral artery haematoma 30.03 18.83 6 13018 120 110576155
Dysuria 29.60 18.83 36 12988 60195 110516080
Hypotonia 29.43 18.83 20 13004 15725 110560550
Urine calcium/creatinine ratio increased 28.79 18.83 6 13018 149 110576126
Vomiting 28.53 18.83 194 12830 910481 109665794
Slow response to stimuli 27.78 18.83 10 13014 1978 110574297
Diabetic metabolic decompensation 27.65 18.83 12 13012 3877 110572398
Pain 27.35 18.83 44 12980 954911 109621364
Metabolic acidosis 27.23 18.83 45 12979 99699 110476576
Urinary incontinence 27.13 18.83 31 12993 48556 110527719
Mast cell degranulation present 26.84 18.83 5 13019 68 110576207
Urethral caruncle 26.64 18.83 5 13019 71 110576204
Death 26.47 18.83 26 12998 698843 109877432
Swelling 25.83 18.83 5 13019 351036 110225239
Chronic kidney disease 25.82 18.83 38 12986 76253 110500022
Product prescribing issue 25.74 18.83 17 13007 12755 110563520
Hypoproteinaemia 25.69 18.83 13 13011 5932 110570343
Peptic ulcer 25.37 18.83 14 13010 7605 110568670
Decreased appetite 25.31 18.83 117 12907 475729 110100546
Insulin-like growth factor decreased 25.09 18.83 7 13017 606 110575669
Lacunar infarction 25 18.83 13 13011 6273 110570002
Bite 24.96 18.83 7 13017 618 110575657
Nasopharyngitis 24.43 18.83 8 13016 394353 110181922
Loss of consciousness 24.35 18.83 64 12960 196242 110380033
Eructation 24.26 18.83 17 13007 14040 110562235
Joint swelling 24.10 18.83 11 13013 442834 110133441
Hypoglycaemic encephalopathy 24.05 18.83 7 13017 706 110575569
Syncope 23.08 18.83 64 12960 202472 110373803
Chest discomfort 22.92 18.83 58 12966 173790 110402485
Muscle rigidity 21.95 18.83 20 13004 24011 110552264
Marasmus 21.75 18.83 8 13016 1683 110574592
Blood glucose increased 21.58 18.83 48 12976 132448 110443827
Portal venous gas 21.44 18.83 6 13018 526 110575749
Urine ketone body present 21.40 18.83 10 13014 3836 110572439
Acetonaemia 21.08 18.83 6 13018 559 110575716
Mucosal erosion 21.02 18.83 9 13015 2815 110573460
Haematemesis 20.81 18.83 30 12994 59078 110517197
Hypersensitivity 20.52 18.83 11 13013 403987 110172288
Mucosal dryness 20.42 18.83 10 13014 4253 110572022
Blood pressure decreased 20.23 18.83 43 12981 115048 110461227
Protein urine present 20.08 18.83 14 13010 11470 110564805
Anuria 19.81 18.83 19 13005 24322 110551953
Monoparesis 19.80 18.83 10 13014 4543 110571732
Motor dysfunction 19.77 18.83 19 13005 24387 110551888
Asthma 19.65 18.83 3 13021 250288 110325987
Micturition disorder 19.50 18.83 10 13014 4688 110571587
Quadriparesis 19.48 18.83 10 13014 4697 110571578
Insulin autoimmune syndrome 19.46 18.83 6 13018 736 110575539

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BD17 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BF01 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Alpha glucosidase inhibitors
FDA MoA N0000000166 alpha Glucosidase Inhibitors
FDA EPC N0000175559 alpha-Glucosidase Inhibitor
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:50627 EC 3.2.1.1 (α-amylase) inhibitor
CHEBI has role CHEBI:67239 EC 3.2.1.20 (α-glucosidase) inhibitor
CHEBI has role CHEBI:176497 geroprotector
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D065089 Glycoside Hydrolase Inhibitors

Related Drugs by ATC class:

A10BD Combinations of oral blood glucose lowering drugs 19 drugs
alogliptincanagliflozindapagliflozinempagliflozinertugliflozinevogliptingemigliptinglimepiridelinagliptinlobeglitazonemetforminphenformin show all 19 →
A10BF Alpha glucosidase inhibitors 2 drugs
miglitolvoglibose

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Cirrhosis of liver contraindication 19943007 DOID:5082
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Ulceration of colon contraindication 46040000
Kidney disease contraindication 90708001 DOID:557
Gastrointestinal obstruction contraindication 126765001
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Surgical procedure contraindication 387713003
Traumatic injury contraindication 417746004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Malabsorption States contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.57 acidic
pKa2 11.95 acidic
pKa3 12.57 acidic
pKa4 13.14 acidic
pKa5 13.89 acidic
pKa6 6.99 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Maltase-glucoamylase, intestinal Enzyme INHIBITOR IC50 5.70 WOMBAT-PK CHEMBL
Pancreatic alpha-amylase Enzyme INHIBITOR IC50 4.49 CHEMBL CHEMBL
Alpha-amylase 1 Enzyme IC50 6 CHEMBL
Lysosomal alpha-glucosidase Enzyme IC50 5.30 CHEMBL
Alpha-amylase 1A Enzyme IC50 6.30 CHEMBL
Sucrase-isomaltase, intestinal Enzyme Ki 6.61 SCIENTIFIC LITERATURE
Sucrase-isomaltase, intestinal Enzyme IC50 6.40 CHEMBL
Lysosomal alpha-glucosidase Enzyme Ki 5.46 CHEMBL
Alpha-amylase Enzyme Ki 6.47 CHEMBL
Oligo-1,6-glucosidase Enzyme IC50 4.42 CHEMBL
Pancreatic alpha-amylase Enzyme IC50 4.45 CHEMBL

External reference:

IDSource
4020940 VUID
N0000148420 NUI
D00216 KEGG_DRUG
151826 RXNORM
C0050393 UMLSCUI
CHEBI:2376 CHEBI
CHEMBL404271 ChEMBL_ID
D020909 MESH_DESCRIPTOR_UI
DB00284 DRUGBANK_ID
6791 IUPHAR_LIGAND_ID
4527 INN_ID
T58MSI464G UNII
9811704 PUBCHEM_CID
136765 MMSL
4117 MMSL
4644 MMSL
d03846 MMSL
4020940 VANDF
004299 NDDF
109077006 SNOMEDCT_US
386965004 SNOMEDCT_US
T58MSI464G INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 0054-0140 TABLET 25 mg ORAL ANDA 10 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 0054-0141 TABLET 50 mg ORAL ANDA 10 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 0054-0142 TABLET 100 mg ORAL ANDA 10 sections
ACARBOSE HUMAN PRESCRIPTION DRUG LABEL 1 11788-039 TABLET 25 mg ORAL ANDA 24 sections
ACARBOSE HUMAN PRESCRIPTION DRUG LABEL 1 11788-040 TABLET 50 mg ORAL ANDA 24 sections
ACARBOSE HUMAN PRESCRIPTION DRUG LABEL 1 11788-041 TABLET 100 mg ORAL ANDA 24 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 23155-147 TABLET 25 mg ORAL ANDA 20 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 23155-148 TABLET 50 mg ORAL ANDA 20 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 23155-149 TABLET 100 mg ORAL ANDA 20 sections
Precose HUMAN PRESCRIPTION DRUG LABEL 1 43353-908 TABLET 50 mg ORAL NDA 22 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 50090-4115 TABLET 50 mg ORAL NDA authorized generic 22 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 50090-4116 TABLET 100 mg ORAL NDA authorized generic 22 sections
ACARBOSE HUMAN PRESCRIPTION DRUG LABEL 1 50090-5088 TABLET 100 mg ORAL ANDA 24 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 50090-5829 TABLET 100 mg ORAL ANDA 17 sections
Precose HUMAN PRESCRIPTION DRUG LABEL 1 54868-5831 TABLET 25 mg ORAL NDA 22 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 54868-5945 TABLET 25 mg ORAL ANDA 19 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 62135-453 TABLET 25 mg ORAL ANDA 21 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 62135-454 TABLET 50 mg ORAL ANDA 21 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 62135-455 TABLET 100 mg ORAL ANDA 21 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 63629-5697 TABLET 25 mg ORAL ANDA 17 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 63629-5698 TABLET 50 mg ORAL ANDA 17 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 64380-758 TABLET 25 mg ORAL ANDA 17 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 64380-759 TABLET 50 mg ORAL ANDA 17 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 64380-760 TABLET 100 mg ORAL ANDA 17 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 68151-0537 TABLET 50 mg ORAL ANDA 17 sections
ACARBOSE HUMAN PRESCRIPTION DRUG LABEL 1 71335-1583 TABLET 50 mg ORAL ANDA 24 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 71335-9725 TABLET 50 mg ORAL ANDA 20 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 72789-131 TABLET 25 mg ORAL ANDA 10 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 72789-132 TABLET 50 mg ORAL ANDA 10 sections
Acarbose HUMAN PRESCRIPTION DRUG LABEL 1 72789-133 TABLET 100 mg ORAL ANDA 10 sections